lepu plus three drops measure the new coronavirus.
Lepu New Coronavirus Antigen Test Kit is a convenient, fast and accurate new coronavirus test product on the market today. The New Coronavirus Antigen Test Kit, on the other hand, can quickly and accurately detect infection with the new coronavirus in a short period of time.
It uses the colloidal gold method, which is simple and easy to operate. Just inject the sample into the kit and wait for 15-20 minutes. You can then determine whether the sample contains the New Crown virus by observing whether color streaks appear in the kit.
At the same time, the product is single-use, avoiding the problem of cross-contamination. The method of use can be said to be very simple, wipe off nasal mucus, put into the nostrils and gently rotate 5 times. Put it into the sample processing liquid tube and rotate it 10 times. Put 3 drops of the liquid onto the test card and leave it for 15-20 minutes to give the results.
In addition to speed, convenience and accuracy, the product is relatively affordable. Compared to traditional nucleic acid tests, it is cheaper per test and more suitable for home use.
Leopold Introduction:
Leopold (Beijing) Medical Devices Co., Ltd. was founded in 1999 by China Shipbuilding Industry Corporation's Seventy-Second Five Research Institute and the U.S. WP Corporation***. The company is mainly engaged in the research and development, production and sales of coronary interventional medical devices, and is one of the few domestic high-end medical devices that can form strong competition with foreign products.
On September 2, 2019, the Ministry of Industry and Information Technology of the People's Republic of China*** and the State of China released the "2019 National Technological Innovation Demonstration Enterprises to be Recognized List of Enterprises Public Notice", and Lepu (Beijing) Medical Devices Company Limited was listed.On March 18, 2020, Lepu Medical Devices was ranked No. 16 of the "2020 Hurun China's 100 Strongest Healthy Private Enterprises" with a market capitalization of RMB 61 billion.
In the past 20 years, the company has been focusing on serving cardiovascular patients, adhering to R&D and innovation, and continuing to make breakthroughs in the fields of cardiovascular stents, pacemakers, cardiovascular drugs, and medical artificial intelligence, etc. The company has also undertaken a number of major national scientific research projects, including the National Development and Reform Commission's High-tech Industrialization Demonstration Project, the Ministry of Science and Technology of the People's Republic of China's 863 Program Development Project, and the Science and Technology Support Program Project. Program, etc.
Currently, the company has developed into a leading high-end medical products industrial group of cardiovascular disease plant interventional diagnostic devices and equipment, covering four major business segments, namely, medical devices, pharmaceutical products, medical services, and new medical business.
The company adheres to the principle of gradual development of "one generation of pre-research, one generation of registration, and one generation of production and sales", and has stepped into the era of bio-absorbable medical devices and artificial AI intelligent medical devices based on coronary drug stents. The company has the second generation of bioabsorbable scaffold NeoVas, a new generation of intravascular drug (paclitaxel)-eluting balloon catheter Vesselin and other heavyweight products.